Form 4: Soleno CCO Meredith Manning Boosts Equity Holdings

Soleno Therapeutics' Chief Commercial Officer Meredith Manning reported the acquisition of 28,600 restricted stock units and 32,800 employee stock options.

Summary

• Meredith Manning, Chief Commercial Officer of Soleno Therapeutics Inc. (SLNO), reported transactions on January 21, 2026.
• Acquired 28,600 restricted stock units (RSUs) of Common Stock at a price of $0, representing a contingent right to receive one share of Common Stock each.
• 100% of these RSUs will vest on December 15, 2027, contingent on continued service as a Service Provider.
• Beneficially owns 72,029 shares of Common Stock following these transactions, including certain other RSUs subject to their own vesting schedules.
• Acquired 32,800 employee stock options (right to buy) with an exercise price of $43.65.
• These options will vest 1/48th on February 1, 2026, and each one-month anniversary thereafter, contingent on continued service as a Service Provider.
• The employee stock options have an expiration date of January 21, 2036.
• Beneficially owns 32,800 derivative securities (employee stock options) following these transactions.

Sentiment

Score: 6

Explanation: The filing reports an insider acquiring additional equity, which generally signals confidence in the company's future prospects. While it's a routine compensation event, it's a positive indicator of management alignment with shareholder interests.

Positives

• Meredith Manning, a key executive, increased her equity holdings in the company, signaling confidence in Soleno Therapeutics' future.
• The acquisition of RSUs and stock options aligns the Chief Commercial Officer's interests with long-term shareholder value creation.
• The vesting schedules for both RSUs (December 15, 2027) and options (monthly over 48 months starting February 1, 2026) incentivize long-term commitment and performance.

Risks

• Vesting of both RSUs and stock options is contingent upon Meredith Manning continuing to be a Service Provider through the specified dates; unvested securities may be forfeited if service terminates.
• The value of the acquired RSUs and stock options is subject to future market price fluctuations of Soleno Therapeutics' Common Stock.
• Future exercise of stock options and conversion of RSUs into common stock could lead to a slight dilution of existing shareholder equity.

Future Outlook

The vesting schedules for the acquired RSUs and stock options extend into December 2027 and January 2036, respectively. This indicates a long-term commitment from the Chief Commercial Officer to the company's performance and growth, aligning her incentives with future shareholder value creation.

Industry Context

The grant of restricted stock units and stock options to a Chief Commercial Officer is a standard practice in the biotechnology and pharmaceutical industries. This form of executive compensation is designed to attract, retain, and motivate key personnel by aligning their financial interests with the long-term success and stock performance of the company. It is a common mechanism for incentivizing executives in growth-oriented sectors like biotech, where long development cycles and regulatory milestones are prevalent.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed in the biotechnology sector.
• Companies like Biogen, Gilead Sciences, and Amgen frequently utilize similar equity-based incentives to retain top talent and encourage long-term strategic focus.
• The specific vesting periods (e.g., 100% on a future date for RSUs, monthly over 48 months for options) are within the common range for executive grants, aiming to ensure sustained commitment.
• The exercise price of $43.65 for the options would typically be set at or above the market price on the grant date, which is standard for incentive stock options.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive signal of management's confidence and alignment with long-term value creation.
• Employees may see standard equity compensation practices as contributing to a positive work environment and retention of key talent.

Next Steps

• Continued service of Meredith Manning to ensure vesting of RSUs and stock options.
• Vesting of 1/48th of stock options monthly, starting February 1, 2026.
• Full vesting of 28,600 RSUs on December 15, 2027.
• Potential exercise of stock options by January 21, 2036.

Key Dates

Keywords

Soleno Therapeutics Inc., SLNO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Employee Stock Option, Executive Compensation, Meredith Manning, Chief Commercial Officer, Equity Incentive Plan